US5434050A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
Assignee: Harvard University
•
Filing: 1991-08-13
•
Granted: 1995-07-18
•
Expires: 2011-08-13
Abstract
Abstract The present invention provides: a labelled beta -amyloid peptide of active fragment; a composition including the labelled beta -amyloid peptide or active fragment thereof and a pharmaceutical carrier; a method for labelling the beta -amyloid peptide or an active fragment thereof, and methods of using the labelled peptide or peptide fragment for detecting or monitoring Alzheimer's disease in a patient.
Inventors
- 👤 John E. Maggio
- 👤 Patrick W. Mantyh
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 15:22
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5091; A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/12; A61K51/1275; C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4711; G01N33/68; G01N33/6893; G01N33/6896; G01N2333/00; G01N2333/435; G01N2333/46; G01N2333/47; G01N2333/4701; G01N2333/4709; G01N2800/00; G01N2800/28; G01N2800/2814; G01N2800/2821; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S530/00; Y10S530/827; Y10S530/839
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
96 words
An in vitro method of screening for Alzheimer's disease in a patient comprising: (a) combining a sample of tissue from the patient with an amount of a labelled β-amyloid peptide or a labelled peptide fragment thereof for a time and under conditions effective to allow binding of the labelled β-amyloid peptide or labelled peptide fragment thereof to human amyloid plaques present in the tissue sample; and (b) detecting the presence of the labelled β-amyloid peptide or labelled peptide fragment thereof bound to amyloid plaques in the tissue sample as a means of screening for Alzheimer's disease.
Claim 2
Dependent Claim
96 words
An in vitro method of screening for Alzheimer's disease in a patient comprising: (a) combining a sample of tissue from the patient with an amount of a labelled β-amyloid peptide or a labelled peptide fragment thereof for a time and under conditions effective to allow binding of the labelled β-amyloid peptide or labelled peptide fragment thereof to human amyloid plaques present in the tissue sample; and (b) detecting the presence of the labelled β-amyloid peptide or labelled peptide fragment thereof bound to amyloid plaques in the tissue sample as a means of screening for Alzheimer's disease.
Claim 3
Dependent Claim
28 words
The method of claim 1 further comprising: (c) quantifying the amount of labelled β-amyloid peptide or labelled peptide fragment thereof bound to amyloid plaques in the tissue sample.
Claim 4
Dependent Claim
128 words
The method of claim 2 further comprising: (d) combining a later-acquired sample of tissue from the patient with an amount of a labelled β-amyloid peptide or a labelled peptide fragment thereof for a time and under conditions effective to allow binding of the labelled β-amyloid peptide or peptide fragment thereof to human amyloid plaques present in the later-acquired tissue sample; (e) quantifying the amount of labelled β-amyloid peptide or labelled peptide fragment thereof bound to amyloid plaques in the later-acquired tissue sample; and (f) comparing the amount of labelled β-amyloid peptide or labelled peptide fragment thereof bound to amyloid plaques in the tissue sample from step (b) with the amount of labelled β-amyloid peptide or labelled peptide fragment thereof bound to amyloid plaques in the later-acquired tissue sample.
Claim 5
Dependent Claim
24 words
The method of claim 1 wherein the β-amyloid peptide that is labelled has the amino acid sequence H-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-OH [SEQ. ID NO:1] prior to labelling.
Claim 6
Dependent Claim
25 words
The method of claim 1 wherein the β-amyloid peptide that is labelled has the amino acid sequence H-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAI IGLMVGGVVIA-OH [SEQ. ID NO:2] prior to labelling.
Claim 7
Dependent Claim
34 words
The method of claim 1 wherein the label of the labelled β-amyloid peptide or labelled peptide fragment thereof comprises a radiolabel, an enzyme label, a fluorescent label, a chemiluminescent label, or an antigen label.
Claim 8
Dependent Claim
43 words
The method of claim 6 wherein the presence of the labelled β-amyloid or labelled peptide fragment thereof bound to amyloid plaques in the tissue sample is detected by autoradiography, positron emission tomography, nuclear magnetic resonance imaging, a gamma counter, or a scintillation counter.
Claim 9
Dependent Claim
11 words
The method of claim 6 wherein the label is a radiolabel.
Claim 10
Dependent Claim
11 words
The method of claim 8 wherein the radiolabel is radioactive iodine.
Claim 11
Dependent Claim
110 words
An in vitro method of screening for Alzheimer's disease in a patient comprising: (a) combining a sample of tissue from the patient with an amount of a radiolabelled β-amyloid peptide having the amino acid sequence H DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-OH [SEQ. ID NO:1], H-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-OH [SEQ. ID NO:2], or a radiolabelled peptide fragment thereof, for a time and under conditions effective to allow binding of the radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof to human amyloid plaques present in the tissue sample; and (b) detecting the presence of the radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof bound to amyloid plaques in the tissue sample as a means of screening for Alzheimer's disease.
Claim 12
Dependent Claim
110 words
An in vitro method of screening for Alzheimer's disease in a patient comprising: (a) combining a sample of tissue from the patient with an amount of a radiolabelled β-amyloid peptide having the amino acid sequence H DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-OH [SEQ. ID NO:1], H-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-OH [SEQ. ID NO:2], or a radiolabelled peptide fragment thereof, for a time and under conditions effective to allow binding of the radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof to human amyloid plaques present in the tissue sample; and (b) detecting the presence of the radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof bound to amyloid plaques in the tissue sample as a means of screening for Alzheimer's disease.
Claim 13
Dependent Claim
11 words
The method of claim 10 wherein the radiolabel is radioactive iodine.
Claim 14
Dependent Claim
147 words
An in vitro method of screening for Alzheimer's disease in a patient comprising: (a) combining a sample of tissue from the patient with an amount of a radiolabelled β-amyloid peptide or a radiolabelled peptide fragment thereof for a time and under conditions effective to allow binding of the radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof to human amyloid plaques present in the tissue sample; and (b) detecting the presence of the radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof bound to amyloid plaques in the tissue sample as a means of screening for Alzheimer's disease; wherein the radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof are obtained by dissolving a purified β-amyloid peptide or peptide fragment thereof in a suitable reaction buffer and performing oxidative radioiodination on the dissolved β-amyloid peptide or peptide fragment thereof to produce a radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof.
Claim 15
Dependent Claim
147 words
An in vitro method of screening for Alzheimer's disease in a patient comprising: (a) combining a sample of tissue from the patient with an amount of a radiolabelled β-amyloid peptide or a radiolabelled peptide fragment thereof for a time and under conditions effective to allow binding of the radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof to human amyloid plaques present in the tissue sample; and (b) detecting the presence of the radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof bound to amyloid plaques in the tissue sample as a means of screening for Alzheimer's disease; wherein the radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof are obtained by dissolving a purified β-amyloid peptide or peptide fragment thereof in a suitable reaction buffer and performing oxidative radioiodination on the dissolved β-amyloid peptide or peptide fragment thereof to produce a radiolabelled β-amyloid peptide or radiolabelled peptide fragment thereof.
Claim 16
Dependent Claim
24 words
The method of claim 12 wherein the β-amyloid peptide that is labelled has the amino acid sequence H-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-OH [SEQ. ID NO:1] prior to labelling.
Claim 17
Dependent Claim
25 words
The method of claim 1 wherein the β-amyloid peptide that is labelled has the amino acid sequence H-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLM VGGVVIA-OH [SEQ. ID NO:2] prior to labelling.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-07-17 | 1999-01-16 | 1999-07-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-07-17 | 2003-01-16 | 2003-07-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-07-17 | 2007-01-16 | 2007-07-18 | $7700.00 | Window Closed / Lapsed |